The failed Checkmate-651 study hints at a survival benefit in some PD-L1 expressers, but will this be enough to file?
Rilzabrutinib flunks a pivotal trial in pemphigus, but all eyes are on tolebrutinib in multiple sclerosis.
The Junshi/Coherus drug only beat chemotherapy, and its study was run not in the US but in China.
The anti-Tigit MAb domvanalimab will generate key clinical results any day; will they be good enough for Gilead to opt in?
The addition of Celgene made Bristol’s sales team pharma’s most productive last year on one measure, but the accolade might be short-lived.